November 17th, 2026GLP-1s Alone Won't Solve Obesity, JAMA Summit Report SaysReport urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.Read more
November 16th, 2026FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation TherapyFDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.Read more
November 16th, 2026Shorter US Residence Linked to Greater CRC Screening NonadherenceNon-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.Read more
November 16th, 2026Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 TrialOnce weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.Read more
November 16th, 2026FDA Approves Weekly Gefurulimab for Generalized Myasthenia GravisThe once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.Read more
November 16th, 2026Alopecia Areata Might Be Tied to Higher Long-Term Glaucoma RiskA TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.Read more
November 16th, 2026β3 Agonists Show No Dementia Advantage Over Anticholinergics in OABβ3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.Read more
November 14th, 2026ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's CostsResearch at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.Read more